ProUroCare Medical Inc. announced the election of Michael Chambers, JD, Ph.D. and James L. Davis to its Board of Directors effective immediately. Michael Chambers is an experienced attorney, angel investor and entrepreneur. Dr. Chambers currently serves as President and CEO of Swift Biotechnology, a company he recently co-founded. Prior to Swift, he helped found InnoRx Pharmaceuticals in 1999, a privately held company that specialized in the development of drugs and drug delivery systems for ocular disease. Mr. Davis is an active investor in ProUroCare and other entrepreneurial companies throughout the U.S. He has considerable experience developing and implementing business and financing strategies for early stage growth companies. He also has previous board experience and has participated in compensation reviews and policy development. Mr. Davis is President of Davis & Associates Inc., a company he founded more than 30 years ago that represents the leading edge lighting and controls manufacturers throughout the upper Midwest.

On December 7, 2009 ProUroCare Medical Inc. entered into a settlement agreement with RPI concerning litigation originally filed by RPI against the company on July 15, 2009. In the complaint, RPI alleged that the company has breached obligations to pay RPI an aggregate of $202,716 under the terms of a license agreement dated July 13, 2001 between RPI and the company and a sponsored research agreement dated as of December 9, 2005 between RPI and the company. In the settlement agreement, the company agreed to pay to RPI a total of $117,000 in installments as follows: $10,000 upon signing, $6,000 per month from December 2009 through October 2010, and $41,000 in November 2010. The company executed an affidavit for judgment by confession to secure the payments. The company has 20 days to cure any failure to make the required payments.

ProUroCare Medical Inc. announced that a 510(k) application for U.S. market clearance of a prostate mechanical imaging system has been filed with the Food & Drug Administration (FDA). The labeling claim for the device is that it can be used as an aid to visualize and document abnormalities of the prostate detected and/or monitored by digital rectal examination (DRE). Under the 510(k) review process, the FDA has 90 days to review the application, although final approval may take longer. The system incorporates the companys unique and patented tactile elasticity imaging technology that creates a map of the prostate and an electronic record that can be stored for future analysis. The prostate imaging systems 510(k) was supported by the results of a recently completed clinical study of 56 patients evaluated at five U.S.

ProUroCare Medical Elects Two New Directors

PROUROCARE MEDICAL INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib

Inclement East Coast Weather Delays ProUroScan(TM) FDA Review

PROUROCARE MEDICAL INC. Files SEC form 10-Q, Quarterly Report

PROUROCARE MEDICAL INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem

ProUroCare Medical Inc. Announces Closing on $1.6 Million Warrant Replacement Offering

ProUroCare Medical Announces Filing of 510(k) For Prostate Imaging System

PROUROCARE MEDICAL INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia

PROUROCARE MEDICAL INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia

ProUroCare Medical Announces Extension of Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants

PROUROCARE MEDICAL INC. Files SEC form 8-K, Other Events

PROUROCARE MEDICAL INC. Files SEC form 10-Q, Quarterly Report